Plus   Neg

Danaher Boosts Q4 Revenue Growth Outlook - Quick Facts

Ahead of President and Chief Executive Officer Rainer Blair commenting on the company's fourth quarter 2020 performance in a presentation at the J.P. Morgan Healthcare Conference later on Wednesday, Danaher Corp. (DHR) said Blair communicate that fourth quarter 2020 core revenue growth including Cytiva is expected to be above the Company's previously announced guidance, driven primarily by better performance in its Life Sciences and Diagnostics segments.

For the fourth quarter 2020, estimated revenues increased approximately 38.5% year-over-year, with approximately 15.0% estimated adjusted core revenue growth including Cytiva.

On average, analysts polled by Thomson Reuters expect the company to report revenue growth of 32.4 percent to $6.44 billion for the quarter.

The company had previously expected adjusted core revenue growth for the fourth quarter, including Cytiva, to be in the low-double digit range.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Netflix Inc. (NFLX) tanked 10% in extended trading session on Tuesday after the online-video streaming giant's first-quarter subscriber additions fell short of expectations. Netflix added 3.98 million subscribers globally in the quarter, far below its forecast of 6.00 million, to end the... Tech giant Apple Inc. (AAPL) on Tuesday held its first product launch event of the year and unveiled new iMac and iPad Pro, which are powered by the latest M1 chips. The Cupertino, California-based company also unveiled AirTag, a lost-device tracking gadget, and an upgraded Apple TV 4K with a new... European Medicines Agency Tuesday said it has found a possible link between the Johnson & Johnson's (JNJ) Covid-19 vaccine and rare blood clots. However, the Europe's medicines regulator pointed out that the overall benefits of getting the vaccine outweigh the risks. EMA's safety committee PRAC concluded...
Follow RTT